Skip to main content
. 2019 Dec 2;4:191. [Version 1] doi: 10.12688/wellcomeopenres.15603.1

Figure 5.

Figure 5.

Comparison of ARIBA, KvarQ, MTBseq, Mykrobe (with final release panel) and TB-Profiler on the prospective dataset for ( a) first-line drugs and ( b) second-line drugs. Counts of susceptible samples are shown on the left, with true-negatives coloured by the tool/panel and false-positives coloured red. Similarly, resistant samples are shown on the right, with true-positives coloured by the tool/panel and false-negatives in red. E, ethambutol; H, isoniazid; Z, pyrazinamide; R, rifampicin; Am, amikacin; Cm, capreomycin; Cfx, ciprofloxacin; Km, kanamycin; Mfx, moxifloxacin; Ofx, ofloxacin; S, streptomycin.